Propofol

The Milk of Amnesia

Drug Spotlight · IV Anesthetic · GABA Modulator

TL;DR

Propofol is the white, milky-looking IV drug you’ve probably seen in an OR, it’s the most commonly used agent to put patients to sleep before surgery. Chemically it’s called 2,6-diisopropylphenol. It works by enhancing the brain’s main “calm down” signal (GABA), which slows everything down: consciousness, breathing, blood pressure. It works in under a minute and wears off quickly, which is why anesthesia providers love it. The flip side is that it has no reversal agent, once you give it, you’re committed to managing the patient until it wears off on its own. That makes dosing and monitoring critical, and it’s exactly why propofol shows up in malpractice cases so often: when things go wrong, they go wrong fast.

Identity

Chemical Profile

Chemical Name

2,6-diisopropylphenol

Formulation

Propofol doesn’t dissolve well in water on its own, it’s an oil. To make it injectable, it’s suspended in a lipid emulsion made from soybean oil and egg lecithin, which is why it looks like skim milk. That same emulsion is a good growth medium for bacteria, so opened vials have to be used or discarded within 12 hours. Something they taught me in my nutrition coursework is that this product is caloric! Since it is suspended in fat, it holds about 1kcal per mL.

Key Properties

Highly fat-soluble: crosses into the brain almost immediately after injection
Spreads rapidly into body tissues, which is why a single dose wears off quickly despite the drug technically staying in your system for hours
Heavily bound to proteins in the blood, only the small free fraction is pharmacologically active
Broken down mainly by the liver, but the liver alone can’t account for how fast it’s cleared, the lungs appear to contribute as well

Chemical Structure

2,6-diisopropylphenol structural formula

Background

History

Before propofol, the go-to IV induction agents had a major problem: patients took a long time to wake up, and some felt groggy for hours afterward. Propofol solved that. Its development wasn’t instant, the compound itself was discovered in the early 1970s, but getting it into a safe, injectable form took over a decade of reformulation.

1973

Researchers at ICI Pharmaceuticals in the UK, led by John Glen, identify 2,6-diisopropylphenol as a potent short-acting sedative while screening a library of phenol compounds. At this point it’s just a promising molecule on paper.
1977

First human trials. The drug works as hoped, but the formulation uses a solubilizing agent called Cremophor EL that causes severe allergic-type reactions in too many patients. This version is scrapped.
1983

The team switches to a soybean oil and egg lecithin emulsion which carries the drug safely without triggering immune reactions. This is the milky-white formulation still in use today.
1986 – 1989

Approved in the UK in 1986 under the brand name Diprivan, then by the FDA in 1989. It quickly becomes the preferred induction agent in most developed countries, replacing older barbiturates like thiopental.
1990s – Present

Use expands to ICU sedation and outpatient procedural sedation. Generic versions flood the market after patent expiry. Propofol also earns a darker kind of notoriety in 2009, Michael Jackson died after his personal physician used it as a sleep aid at home, a fundamentally inappropriate use that sparked widespread public awareness of the drug.

Pharmacology

How It Works

The brain stays conscious because neurons are constantly firing signals back and forth. One of the brain’s main ways of quieting that activity is through a neurotransmitter called GABA, which binds to receptors on neurons and makes them harder to excite. Propofol works by latching onto those same GABA receptors and amplifying their effect essentially turning up the brain’s natural “off switch.” The result is a rapid, dose dependent depression of consciousness, and at higher doses, a near complete suppression of brain activity.

Because propofol is so fat soluble, it crosses into the brain within seconds of being injected. The reason a single dose wears off so quickly isn’t because the drug disappears it’s because it rapidly redistributes out of the brain and into muscle and fat tissue, dropping the brain concentration below the threshold needed to maintain sedation. With a continuous infusion though, those peripheral tissues gradually fill up, and the drug starts to linger longer. This is an important distinction for anesthesia providers managing longer cases.

Dosing at a Glance

Induction (putting patient to sleep): ~1.5–2.5 mg/kg · Maintenance (keeping asleep): continuous infusion · Sedation (MAC): lower-dose infusion · Onset: ~30–60 seconds · Single-dose duration: ~5–10 min

Anesthetic Practice

Clinical Application

Propofol is used across a wide range of settings, from brief office procedures to full surgical anesthesia to sedation in the ICU. Its appeal is that it’s fast, titratable, and patients tend to wake up feeling clear-headed rather than foggy.

Induction of general anesthesia: This is propofol’s most classic use. A bolus dose is given IV and the patient is unconscious within one arm-to-brain circulation time. Providers often give a small dose of IV lidocaine first to reduce the burning sensation propofol can cause on injection.
Total IV anesthesia (TIVA): Instead of using inhaled gases to maintain anesthesia, some providers run a continuous propofol infusion throughout the case. This is common when avoiding volatile anesthetics is preferred for example, in patients at risk for malignant hyperthermia.
MAC / Procedural sedation: For procedures like colonoscopies or endoscopies that don’t require full general anesthesia, propofol is infused at a lower dose to keep the patient sedated. The challenge is that the line between “sedated” and “fully asleep” can blur quickly, especially with additional pain medications on board.
ICU sedation: Propofol is used to keep mechanically ventilated patients comfortable. One serious complication of prolonged high-dose infusions is propofol infusion syndrome (PRIS) a rare but life-threatening condition involving metabolic acidosis, muscle breakdown, and cardiac failure. This risk is why ICU teams closely monitor patients on extended propofol drips.
Antiemetic adjunct: At very small sub-sedating doses, propofol has a surprisingly effective anti-nausea effect. It’s sometimes given at the end of a case to prevent postoperative nausea and vomiting (PONV).

Body-Wide Effects

Cardiovascular: Propofol causes blood pressure to drop, sometimes significantly. It relaxes blood vessels and slightly suppresses the heart’s pumping force. This is manageable in healthy patients but can be a problem in someone who is already hemodynamically unstable or elderly.
Respiratory: This is the big one. Propofol suppresses the drive to breathe, and a standard induction dose will cause a patient to stop breathing for a short period (apnea). Even at sedation doses, it blunts the body’s normal response to rising CO₂ levels. When combined with opioids like fentanyl — which do the same thing — the effect is much stronger than either drug alone.
CNS: Reduces brain oxygen demand and blood flow, which is actually useful in neurosurgical cases. At high doses it produces burst suppression on EEG, basically the brain’s electrical activity going mostly quiet.
Contraindications: Patients with allergies to soy or eggs should be treated with caution given the lipid emulsion vehicle. Not approved for sedation in children under 3 years old due to safety concerns.

Medicolegal

Litigation Themes

Given how often propofol is used, it’s not surprising that it comes up frequently in malpractice cases. What is striking is that the same handful of situations keeps appearing in the case law over and over. These aren’t freak accidents — they’re predictable consequences of propofol’s pharmacology in specific high-risk scenarios.

MAC becoming unintentional general anesthesia: Sedation exists on a continuum. A patient under MAC can slide into full general anesthesia, losing their airway protective reflexes without anyone realizing it until something goes wrong. Plaintiffs frequently argue that the provider failed to recognize and respond to this transition in time.
Opioid co-administration in high-risk patients: Giving propofol alongside a narcotic like fentanyl is routine but in patients with obstructive sleep apnea, obesity, or other risk factors, the combined respiratory suppression can be dangerous. Cases often scrutinize whether the dosing was appropriate and whether monitoring was adequate for the patient’s risk profile.
Delayed airway intervention: When a patient stops breathing or desaturates, every second counts. Anesthesia records are used to reconstruct exactly how long it took to respond. A delay of even two to three minutes in a patient whose oxygen is dropping can be nearly impossible to defend in court.
Diversion and misuse: Because propofol is not a DEA-scheduled drug, its tracking has historically been less rigorous than narcotics. This has made it a target for diversion by healthcare workers sometimes resulting in patient harm when syringes are tampered with or diluted.

References

Bryson HM, Fulton BR, Faulds D. Propofol: an update of its use in anaesthesia and conscious sedation. Drugs. 1995;50(3):513–559.
Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in anesthesia: mechanism of action, structure–activity relationships, and drug delivery. Curr Med Chem. 2000;7(2):249–271.
Sahinovic MM, Struys MMRF, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57(12):1539–1558.
FDA. Diprivan (propofol) prescribing information. AstraZeneca.
Domino KB, Posner KL, Caplan RA, Cheney FW. Awareness during anesthesia: a closed claims analysis. Anesthesiology. 1999;90(4):1053–1061.